Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Burchert A, Nicolini FE, le Coutre P, Saussele S, Hochhaus A, Tuere E, Metzelder SK, Pauck K, Garn H, Raifer H, Huber M, Gattermann N, Crysandt M, Schafhausen P, Bormann M, Radsak MP, Guerci-Bresler A, Illmer T, Goebeler ME, Herhaus P, Teichmann LL, Franke GN, Lang F, Krause SW, Möhle R, Klausmann M, Stegelmann F, Lutz C, Etienne G, Stoltefuß A, Göthert JR, Ernst T, Abu-Samra M, Höffkes HG, Neubauer A, Wang Y, Weiland P, Otto C, Kiessler L, Weber T, Kroning L, Nist A, Stiewe T, Hehlmann R, Aminossadati B, Wittenberg M, Winterstein K, Oellerich T, Lechner M, Pfirrmann M, Schade-Brittinger C, Klemm P, Michel C.

Open source

DOI: 10.1038/s41375-025-02859-1
Published: 2026-01-12
Container: Leukemia
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41375-025-02859-1,
  title = {Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).},
  author = {Burchert A and  Nicolini FE and  le Coutre P and  Saussele S and  Hochhaus A and  Tuere E and  Metzelder SK and  Pauck K and  Garn H and  Raifer H and  Huber M and  Gattermann N and  Crysandt M and  Schafhausen P and  Bormann M and  Radsak MP and  Guerci-Bresler A and  Illmer T and  Goebeler ME and  Herhaus P and  Teichmann LL and  Franke GN and  Lang F and  Krause SW and  Möhle R and  Klausmann M and  Stegelmann F and  Lutz C and  Etienne G and  Stoltefuß A and  Göthert JR and  Ernst T and  Abu-Samra M and  Höffkes HG and  Neubauer A and  Wang Y and  Weiland P and  Otto C and  Kiessler L and  Weber T and  Kroning L and  Nist A and  Stiewe T and  Hehlmann R and  Aminossadati B and  Wittenberg M and  Winterstein K and  Oellerich T and  Lechner M and  Pfirrmann M and  Schade-Brittinger C and  Klemm P and  Michel C.},
  year = {2026},
  journal = {Leukemia},
  doi = {10.1038/s41375-025-02859-1},
  url = {https://doi.org/10.1038/s41375-025-02859-1}
}

RIS

TY  - JOUR
TI  - Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).
AU  - Burchert A
AU  -  Nicolini FE
AU  -  le Coutre P
AU  -  Saussele S
AU  -  Hochhaus A
AU  -  Tuere E
AU  -  Metzelder SK
AU  -  Pauck K
AU  -  Garn H
AU  -  Raifer H
AU  -  Huber M
AU  -  Gattermann N
AU  -  Crysandt M
AU  -  Schafhausen P
AU  -  Bormann M
AU  -  Radsak MP
AU  -  Guerci-Bresler A
AU  -  Illmer T
AU  -  Goebeler ME
AU  -  Herhaus P
AU  -  Teichmann LL
AU  -  Franke GN
AU  -  Lang F
AU  -  Krause SW
AU  -  Möhle R
AU  -  Klausmann M
AU  -  Stegelmann F
AU  -  Lutz C
AU  -  Etienne G
AU  -  Stoltefuß A
AU  -  Göthert JR
AU  -  Ernst T
AU  -  Abu-Samra M
AU  -  Höffkes HG
AU  -  Neubauer A
AU  -  Wang Y
AU  -  Weiland P
AU  -  Otto C
AU  -  Kiessler L
AU  -  Weber T
AU  -  Kroning L
AU  -  Nist A
AU  -  Stiewe T
AU  -  Hehlmann R
AU  -  Aminossadati B
AU  -  Wittenberg M
AU  -  Winterstein K
AU  -  Oellerich T
AU  -  Lechner M
AU  -  Pfirrmann M
AU  -  Schade-Brittinger C
AU  -  Klemm P
AU  -  Michel C.
PY  - 2026
JO  - Leukemia
DO  - 10.1038/s41375-025-02859-1
UR  - https://doi.org/10.1038/s41375-025-02859-1
ER  -

APA

A, B., FE, N., P, L. C., S, S., A, H., E, T., SK, M., K, P., H, G., H, R., M, H., N, G., M, C., P, S., M, B., MP, R., A, G., T, I., ME, G., P, H., LL, T., GN, F., F, L., SW, K., R, M., M, K., F, S., C, L., G, E., A, S., JR, G., T, E., M, A., HG, H., A, N., Y, W., P, W., C, O., L, K., T, W., L, K., A, N., T, S., R, H., B, A., M, W., K, W., T, O., M, L., M, P., C, S., P, K., & C., M. (2026). Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).. Leukemia. https://doi.org/10.1038/s41375-025-02859-1

Source records

europe-pmc · retrieved 2026-09-27T12:02:05.155Z